Blood-pressure-lowering peptide (EGPKLVAS)
A small peptide that blocks ACE, an enzyme that raises blood pressure, used only as a lab research tool.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
Literature-extracted sequence peptide — synthesized for bioassay as documented in linked reference(s)
Fork this card to add platform evidence →
Activity measured in linked reference(s) — IC50/MIC/cytotoxicity data
Fork this card to add platform evidence →
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Could reshaping this peptide into a closed loop stop stomach enzymes from breaking it down before it works?
Most food-derived blood-pressure peptides fall apart in the gut before they can act. If this chemical modification holds up in testing, it could mean a more effective oral supplement or drug that works at a lower dose, for people managing hypertension.
Does this peptide work on a second enzyme that current testing has missed, giving it a stronger effect on blood pressure?
A peptide that inhibits two separate blood-pressure pathways at once could be more potent than one acting alone. If confirmed, this could make it a candidate food-derived alternative to combination drugs, for people looking for natural cardiovascular support.
Could stomach enzymes chew off the first building block of this peptide and release a stronger fragment that does the real work?
If this peptide turns out to be a precursor that gets activated during digestion rather than degraded, it would mean lab measurements of its potency are actually underestimates. That would change how researchers dose and formulate it, which matters for anyone developing it as a supplement or drug.
Beyond lowering blood pressure, could this peptide also reduce the vessel wall inflammation that drives heart disease?
Vascular inflammation is an early step toward atherosclerosis and heart attacks, even in people without high blood pressure. If this peptide can reduce that inflammation through its known mechanism, it could be useful for a much wider group, including people in early-stage metabolic or cardiovascular risk.
Does this peptide bind to the particular part of the ACE enzyme that could give it a cleaner safety profile than common blood-pressure drugs?
Some ACE inhibitors cause a persistent dry cough because they act on the wrong part of the enzyme. If this peptide turns out to bind only the preferred part, it could potentially avoid that side effect, which would be meaningful for patients who cannot tolerate standard ACE inhibitor medications.
Does one unusually flexible amino acid in the middle of this peptide act as a pivot that lets the whole chain fold into the right shape for binding?
If one building block controls the peptide's folding into an active shape, chemists could replace it with a version that locks that shape permanently. That could improve both potency and stability, which is a step toward turning a food-derived peptide into a practical drug candidate.
Does the electric charge of this peptide steer it toward only one of the two working ends of the ACE enzyme, avoiding the side that interferes with other body processes?
ACE inhibitor drugs work on both halves of their target enzyme, and one half is linked to side effects like anemia. If this peptide naturally avoids that half, it could offer blood-pressure lowering with a narrower set of risks, which would matter for long-term use or for patients sensitive to current medications.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.8366782069206238 | boltz-2 |
| ranking score | 0.8838370442390442 | boltz-2 |
▸structural qualityopenfold3
| metric | value | note |
|---|---|---|
| gpde | 0.697 | global PDE — lower = better |
| disorder | NaN | fraction disordered |
▸3-letter notation
▸recipeboltz-2 1.0
| parameter | value |
|---|---|
| model | boltz-2 1.0 |
| weights | — |
| hardware | nvidia_nim_api |
| mlx version | — |
| python | — |
| random seed | — |
| msa strategy | none |
| diffusion samples | 1 |
| runtime | — |
| predicted by | mlx@peptide |
| predicted at | 2026-04-24 |
▸citationbibtex
@peptide{pep04741,
sequence = {EGPKLVAS},
target = {ace},
author = {peptidemodel},
year = {2026},
status = {bioassayed}
}